PRTA
Prothena Corporation plc Ordinary Shares
Nasdaq · usd
Stock performance
How Prothena Corporation plc Ordinary Shares (PRTA) stock has performed from one day to one year, with its 52-week range.
- 1D
- -2.33%
- 1W
- -9.17%
- 1M
- -4.55%
- YTD
- -16.54%
- 1Y
- -23.07%
- 52-wk range
- $7.73 – $11.80
Key statistics
Today's trading snapshot for PRTA: day range, open, previous close, volume and market cap.
- Day range
- —
- Open
- —
- Prev close
- $7.97
- Volume
- 0
- Market cap
- $419.01M
- Shares out
- 51.35M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Prothena Corporation plc Ordinary Shares: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 7.95
- P/B
- 1.56
- P/FCF
- —
- ROE
- -8.9%
- ROA
- -8.5%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 13, 2026
8-K filings
Material corporate events Prothena Corporation plc Ordinary Shares has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 5, 2026
On November 5, 2026, Prothena Corporation plc issued a press release announcing its financial results for the third quarter ended September 30, 2026.
- Business updateOct 29, 2026
Moponetug and PRX019 are both clinical-stage programs which were part of a research and development collaboration with Bristol Myers Squibb executed in 2018. Bristol Myers Squibb continues to develop moponetug (formerly PRX005), a potential best-in-class antibody for the treatment of Alzheimer's disease ...
- Executive officer departureOct 2, 2026
On October 2, 2026, Chad J. Swanson, Ph.D., Chief Development Officer of Prothena Corporation plc (the "Company") notified the Company that he is resigning from the Company effective October 9, 2026. Dr. Swanson is resigning to accept a position with one of the Company's strategic partners, and, as part of his new role, will assume a leadership role over a program partnered with the Company.
- Annual meeting resultsMay 15, 2026
On May 14, 2026, Prothena Corporation plc (the "Company") held its annual general meeting of shareholders, at which the Company's shareholders voted on the following proposals... Proposal No. 1: Election of Directors. The shareholders re-elected the following individuals to the Company's Board of Directors to hold office until no later than the annual general meeting of shareholders in 2029.
- Share repurchase programFeb 27, 2026
On February 27, 2026, the Company announced a share repurchase plan under which the Company may repurchase up to $100.0 million of the Company's outstanding ordinary shares, par value $0.01 per share. The share repurchase plan will expire on December 31, 2026, may be suspended or discontinued at any time, and does not obligate the company to acquire any amount of ordinary shares.
PRTA short interest
How heavily PRTA is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 15.7
- Short interest
- 7.91M
- Avg volume
- 504.2K
As of · reported to FINRA twice monthly.
PRTA news
The latest news and headlines about Prothena Corporation plc Ordinary Shares (PRTA).
- Wall Street Analysts See a 120.16% Upside in Prothena (PRTA): Can the Stock Really Move This High?positiveZacks Investment Research· Nov 10, 2026
- Prothena (PRTA) Reports Q3 Loss, Misses Revenue EstimatesnegativeZacks Investment Research· Nov 5, 2026
- Prothena's Partnership Strategy: Growth Driver or Limitation?positiveZacks Investment Research· Oct 20, 2026
- CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?positiveZacks Investment Research· Oct 8, 2026
- Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS InsiderpositiveGlobeNewswire Inc.· Jul 7, 2026
Frequently asked questions
What is the Prothena Corporation plc Ordinary Shares (PRTA) stock price today?
Massive provides real-time and historical Prothena Corporation plc Ordinary Shares (PRTA) quotes via REST API, WebSocket and MCP.
What is Prothena Corporation plc Ordinary Shares?
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases.
What is the short interest in PRTA?
As of Oct 30, 2026, PRTA has 7.91M shares short and 15.7 days to cover.
What exchange is PRTA listed on?
Prothena Corporation plc Ordinary Shares (PRTA) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of PRTA with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a PRTA analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.